Lotte Biologics Co., Ltd announced a placement of 2,615,200 common shares at an issue price of KRW 65,000 per share for gross proceeds of KRW 169,988,000,000 on March 24, 2023. The transaction will include participation from returning investor, LOTTE Corporation. The transaction has been approved by board of directors of the company.

The transaction will be carried on four installments, on April 10, 2023, June 8, 2023, June 8, 2023 and December 7, 2023.